The contributions of multidrug resistant clones to the success of pandemic extra-intestinal Pathogenic Escherichia coli

References

• Baquero F. Threats of antibiotic resistance: an obliged reappraisal. Int Microbiol. 2021 May;24(4):499–506.
   PubMed Web of Science ®Google Scholar
• Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629–655.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318–327.
   PubMed Web of Science ®Google Scholar
• Baker S, Thomson N, Weill FX, et al. Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens. Science. 2018 May 18;360(6390):733–738.
   PubMed Web of Science ®Google Scholar
• Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015 Jul;28(3):565–591.
   PubMed Web of Science ®Google Scholar
• Partridge SR, Kwong SM, Firth N, et al. Mobile Genetic Elements Associated with Antimicrobial Resistance. Clin Microbiol Rev. 2018 Oct;31(4):e00088–17.
   PubMed Web of Science ®Google Scholar
• Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011 Sep;35(5):736–755.
   PubMed Web of Science ®Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Holland MS, Nobrega D, Peirano G, et al. Molecular epidemiology of Escherichia coli causing bloodstream infections in a centralized Canadian region: a population-based surveillance study. Clin Microbiol Infect. 2020 Nov;26(11):1554e1–1554 e8.
   Google Scholar
• Pitout JDD. Population Dynamics of Escherichia coli Causing Bloodstream Infections over Extended Time Periods. mSphere. 2021 Dec 22;6(6):e0095621.
   PubMedGoogle Scholar
• Peirano G, Chen L, Kreiswirth BN, et al. Emerging Antimicrobial-Resistant High-Risk Klebsiella pneumoniae Clones ST307 and ST147. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e01148–20.
   PubMedGoogle Scholar
• Baquero F, Martinez JL, FL V, et al. Evolutionary Pathways and Trajectories in Antibiotic Resistance. Clin Microbiol Rev. 2021 Jun; 30e0005019.
   Google Scholar
• Pitout JD. Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance. Front Microbiol. 2012;3:9.
   PubMed Web of Science ®Google Scholar
• Laupland KB, Church DL. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev. 2014 Oct;27(4):647–664.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect. 2014 Sep;20(9):821–830.
   PubMed Web of Science ®Google Scholar
• Bonten M, Johnson JR, van den Biggelaar AHJ, et al. Epidemiology of Escherichia coli Bacteremia: A Systematic Literature Review. Clin Infect Dis. 2021 Apr 8;72(7):1211–1219.
   PubMed Web of Science ®Google Scholar
• Naylor NR, Pouwels KB, Hope R, et al. The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the English hospital setting: A national retrospective cohort study. PLoS One. 2019;14(9):e0221944.
   PubMed Web of Science ®Google Scholar
• Leger A, Lambraki I, Graells T, et al. Characterizing social-ecological context and success factors of antimicrobial resistance interventions across the One Health spectrum: analysis of 42 interventions targeting E. coli. BMC Infect Dis. 2021 Aug 26;21(1):873.
   PubMedGoogle Scholar
• Pitout JD. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Rev Anti Infect Ther. 2012;Oct;10(10):1165–1176.
   PubMedGoogle Scholar
• Pitout JD, Chan WW, Church DL. Tackling antimicrobial resistance in lower urinary tract infections: treatment options. Expert Rev Anti Infect Ther. 2016 Jul;14(7):621–632.
   PubMed Web of Science ®Google Scholar
• Peirano G, Pitout JDD. Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options. Drugs. 2019 Sep;79(14):1529–1541.
   PubMed Web of Science ®Google Scholar
• Tompkins K, van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2053–2068.
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011 Nov;55(11):4943–4960.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery and Development of New Antibiotics Essential medicines and health products [cited 2017 Nov]. Available from: https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/2017
   Google Scholar
• Fuzi M, Rodriguez Bano J, Toth A. Global Evolution of Pathogenic Bacteria With Extensive Use of Fluoroquinolone Agents. Front Microbiol. 2020;11:271.
   PubMedGoogle Scholar
• Huseby DL, Pietsch F, Brandis G, et al. Mutation Supply and Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli. Mol Biol Evol. 2017 May 1;34(5):1029–1039.
   PubMedGoogle Scholar
• Peirano G, van der Bij AK, Gregson DB, et al. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum beta-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012 Feb;50(2):294–299.
   PubMedGoogle Scholar
• Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother. 2017 Aug 1;72(8):2145–2155.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Pitout JD, Gomi R, et al. Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene. Emerg Infect Dis. 2016 Nov;22(11):1900–1907.
   PubMedGoogle Scholar
• Pitout JD, Nordmann P, Carbapenemase-Producing PL. Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance. Antimicrob Agents Chemother. 2015 Oct;59(10):5873–5884.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Kazmierczak KM, et al. In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017. J Glob Antimicrob Resist. 2020 Jun; 21223–228.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Karlowsky JA, de Jonge BLM, et al. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0200020.
   PubMed Web of Science ®Google Scholar
• Peirano G, Chen L, Nobrega D, et al. Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015-2017. Emerg Infect Dis. 2022 May;28(5):924–931.
   PubMedGoogle Scholar
• Manges AR, Geum HM, Guo A, et al. Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages. Clin Microbiol Rev. 2019 Jun 19;32:3.
   Google Scholar
• Cummins EA, Snaith AE, McNally A, et al. The role of potentiating mutations in the evolution of pandemic Escherichia coli clones. Eur J Clin Microbiol Infect Dis. 2021 Nov;17. DOI:10.1007/s10096-021-04359-3.
   Google Scholar
• Peirano G, Bradford PA, Kazmierczak KM, et al. Global incidence of carbapenemase-producing Escherichia coli ST131. Emerg Infect Dis. 2014 Nov;20(11):1928–1931.
   PubMedGoogle Scholar
• Roer L, Overballe-Petersen S, Hansen F, et al. Escherichia coli Sequence Type 410 Is Causing New International High-Risk Clones. mSphere. 2018 Jul 18;3(4):e00337–18.
   PubMedGoogle Scholar
• Mathers AJ, Peirano G, Pitout JD. Escherichia coli ST131: The quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol. 2015;90:109–154.
   PubMed Web of Science ®Google Scholar
• Ben Zakour NL, Alsheikh-Hussain AS, Ashcroft MM, et al. Sequential Acquisition of Virulence and Fluoroquinolone Resistance Has Shaped the Evolution of Escherichia coli ST131. mBio. 2016 Apr 26;7(2):e00347–16.
   PubMed Web of Science ®Google Scholar
• Chen L, Peirano G, Kreiswirth BN, et al. Acquisition of genomic elements were pivotal for the success of Escherichia coli ST410. J Antimicrob Chemother. 2022 Oct;77(12):3399–3407.
   PubMedGoogle Scholar
• Pitout JDD, Peirano G, Chen L, et al. Escherichia coli ST1193: Following in the Footsteps of E. coli ST131. Antimicrob Agents Chemother. 2022;Jun(6):e0051122.
   Google Scholar
• Platell JL, Trott DJ, Johnson JR, et al. Prominence of an O75 clonal group (clonal complex 14) among non-ST131 fluoroquinolone-resistant Escherichia coli causing extraintestinal infections in humans and dogs in Australia. Antimicrob Agents Chemother. 2012 Jul;56(7):3898–3904.
   PubMedGoogle Scholar
• Cremet L, Caroff N, Giraudeau C, et al. Detection of clonally related Escherichia coli isolates producing different CMY beta-lactamases from a cystic fibrosis patient. J Antimicrob Chemother. 2013 May;68(5):1032–1035.
   PubMedGoogle Scholar
• Chang J, Yu J, Lee H, et al. Prevalence and characteristics of lactose non-fermenting Escherichia coli in urinary isolates. J Infect Chemother. 2014 Nov;20(11):738–740.
   PubMedGoogle Scholar
• Kim Y, Oh T, Nam YS, et al. Prevalence of ST131 and ST1193 Among Bloodstream Isolates of Escherichia coli not Susceptible to Ciprofloxacin in a Tertiary Care University Hospital in Korea, 2013-2014. Clin Lab. 2017 Sep 1;63(9):1541–1543.
   PubMedGoogle Scholar
• Matsumura Y, Pitout JDD, Peirano G, et al. Rapid Identification of Different Escherichia coli Sequence Type 131 Clades. Antimicrob Agents Chemother. 2017 Aug;61(8):e00179–17.
   PubMedGoogle Scholar
• Wu J, Lan F, Lu Y, et al. Molecular Characteristics of ST1193 Clone among Phylogenetic Group B2 Non-ST131 Fluoroquinolone-Resistant Escherichia coli. Front Microbiol. 2017;8:2294.
   PubMedGoogle Scholar
• Xia L, Liu Y, Xia S, et al. Prevalence of ST1193 clone and IncI1/ST16 plasmid in E-coli isolates carrying blaCTX-M-55 gene from urinary tract infections patients in China. Sci Rep. 2017 Mar 24;7:44866.
   PubMedGoogle Scholar
• Xia S, Fan X, Huang Z, et al. Dominance of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS One. 2014;9(7):e100707.
   PubMedGoogle Scholar
• Zhao L, Zhang J, Zheng B, et al. Molecular epidemiology and genetic diversity of fluoroquinolone-resistant Escherichia coli isolates from patients with community-onset infections in 30 Chinese county hospitals. J Clin Microbiol. 2015 Mar;53(3):766–770.
   PubMedGoogle Scholar
• Peirano G, Matsumara Y, Nobrega D, et al. Population-based epidemiology of Escherichia coli ST1193 causing blood stream infections in a centralized Canadian region. Eur J Clin Microbiol Infect Dis. 2021 Nov;9. DOI:10.1007/s10096-021-04373-5.
   PubMedGoogle Scholar
• Johnson TJ, Elnekave E, Miller EA, et al. Phylogenomic Analysis of Extraintestinal Pathogenic Escherichia coli Sequence Type 1193, an Emerging Multidrug-Resistant Clonal Group. Antimicrob Agents Chemother. 2019 Jan;63(1):e01913–18.
   PubMedGoogle Scholar
• Tchesnokova V, Radey M, Chattopadhyay S, et al. Pandemic fluoroquinolone resistant Escherichia coli clone ST1193 emerged via simultaneous homologous recombinations in 11 gene loci. Proc Natl Acad Sci U S A. 2019 Jul 16;116(29):14740–14748.
   PubMedGoogle Scholar
• Johnson JR, Johnston BD, Porter SB, et al. Rapid Emergence, Subsidence, and Molecular Detection of Escherichia coli Sequence Type 1193-fimH64, a New Disseminated Multidrug-Resistant Commensal and Extraintestinal Pathogen. J Clin Microbiol. 2019 May;57(5):e01664–18.
   PubMedGoogle Scholar
• Valenza G, Werner M, Eisenberger D, et al. First report of the new emerging global clone ST1193 among clinical isolates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli from Germany. J Glob Antimicrob Resist. 2019 Jun; 17305–308.
   PubMedGoogle Scholar
• Zeng Q, Xiao S, Gu F, et al. Antimicrobial Resistance and Molecular Epidemiology of Uropathogenic Escherichia coli Isolated From Female Patients in Shanghai, China. Front Cell Infect Microbiol. 2021;11:653983.
   PubMedGoogle Scholar
• Cherubini S, Perilli M, Azzini AM, et al. Resistome and Virulome of Multi-Drug Resistant E. coli ST131 Isolated from Residents of Long-Term Care Facilities in the Northern Italian Region. Diagnostics (Basel). 2022 Jan 16;12(1):213.
   PubMedGoogle Scholar
• Gomes DJ, Bardossy AC, Chen L, et al. Transmission of novel Klebsiella pneumoniae carbapenemase-producing Escherichia coli sequence type 1193 among residents and caregivers in a community-based, residential care setting-Nevada, 2018. Infect Control Hosp Epidemiol. 2020 Nov;41(11):1341–1343.
   PubMedGoogle Scholar
• Al-Farsi HM, Camporeale A, Ininbergs K, et al. Clinical and molecular characteristics of carbapenem non-susceptible Escherichia coli: A nationwide survey from Oman. PLoS One. 2020;15(10):e0239924.
   PubMedGoogle Scholar
• Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis. 2008 Feb;14(2):195–200.
   PubMed Web of Science ®Google Scholar
• Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25: H4-ST131producing CTX-M-15. J Antimicrob Chemother. 2008 Feb;61(2):273–281.
   PubMed Web of Science ®Google Scholar
• Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010 Apr;35(4):316–321.
   PubMed Web of Science ®Google Scholar
• Peirano G, Pitout JD. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother. 2014 May;58(5):2699–2703.
   PubMedGoogle Scholar
• Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev. 2014 Jul;27(3):543–574.
   PubMed Web of Science ®Google Scholar
• Petty NK, Ben Zakour NL, Stanton-Cook M, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5694–5699.
   PubMed Web of Science ®Google Scholar
• Pitout JDD, Finn TJ. The evolutionary puzzle of Escherichia coli ST131. Infect Genet Evol. 2020 Jul;81:104265.
   PubMedGoogle Scholar
• Decano AG, Downing T. An Escherichia coli ST131 pangenome atlas reveals population structure and evolution across 4,071 isolates. Sci Rep. 2019 Nov 22;9(1):17394.
   PubMed Web of Science ®Google Scholar
• Peirano G, van der Bij AK, Freeman JL, et al. Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum beta-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother. 2014 Jul;58(7):3762–3767.
   PubMed Web of Science ®Google Scholar
• Pitout JD, DeVinney R. Escherichia coli ST131: a multidrug-resistant clone primed for global domination. F1000Res. 2017;6.
   Google Scholar
• Peirano G, Lynch T, Matsumara Y, et al. Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006-2016(1). Emerg Infect Dis. 2020 Dec;26(12):2907–2915.
   PubMedGoogle Scholar
• Johnson JR, Johnston B, Kuskowski MA, et al. Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli. Antimicrob Agents Chemother. 2015 Aug;59(8):4471–4480.
   PubMed Web of Science ®Google Scholar
• Phan MD, Peters KM, Alvarez Fraga L, et al. Plasmid-Mediated Ciprofloxacin Resistance Imparts a Selective Advantage on Escherichia coli ST131. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0214621.
   PubMedGoogle Scholar
• Carattoli A, Zankari E, Garcia-Fernandez A, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother. 2014 Jul;58(7):3895–3903.
   PubMed Web of Science ®Google Scholar
• Johnson TJ, Danzeisen JL, Youmans B, et al. Separate F-Type Plasmids Have Shaped the Evolution of the H30 Subclone of Escherichia coli Sequence Type 131. J Clin Microbio. 2019 April;57(5):e01664–18.
   PubMedGoogle Scholar
• Johnston BD, Thuras P, Porter SB, et al. Global molecular epidemiology of carbapenem-resistant Escherichia coli (2002-2017). Eur J Clin Microbiol Infect Dis. 2021 Jul;19. DOI:10.1007/s10096-021-04310-6.
   Google Scholar
• Coelho A, Mora A, Mamani R, et al. Spread of Escherichia coli O25b: H4-B2-ST131producing CTX-M-15 and SHV-12 with high virulence gene content in Barcelona (Spain). J Antimicrob Chemother. 2011 Mar;66(3):517–526.
   PubMedGoogle Scholar
• Peirano G, Asensi MD, Pitondo-Silva A, et al. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from Rio de Janeiro, Brazil. Clin Microbiol Infect. 2011 Jul;17(7):1039–1043.
   PubMedGoogle Scholar
• Mushtaq S, Irfan S, Sarma JB, et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother. 2011 Sep;66(9):2002–2005.
   PubMed Web of Science ®Google Scholar
• Qin S, Zhou M, Zhang Q, et al. First identification of NDM-4-producing Escherichia coli ST410 in China. Emerg Microbes Infect. 2016 Nov 23;5(11):e118.
   PubMedGoogle Scholar
• Liu Y, Feng Y, Wu W, et al. First Report of OXA-181-Producing Escherichia coli in China and Characterization of the Isolate Using Whole-Genome Sequencing. Antimicrob Agents Chemother. 2015 Aug;59(8):5022–5025.
   PubMed Web of Science ®Google Scholar
• Timofte D, Maciuca IE, Williams NJ, et al. Veterinary Hospital Dissemination of CTX-M-15 Extended-Spectrum Beta-Lactamase-Producing Escherichia coli ST410 in the United Kingdom. Microb Drug Resist. 2016 Oct;22(7):609–615.
   PubMedGoogle Scholar
• Howard JC, Anderson T, Creighton J, et al. Geographical and temporal clustering of OXA-48-producing Escherichia coli ST410 causing community-onset urinary tract infection in Christchurch, New Zealand. J Antimicrob Chemother. 2018 Oct 1;73(10):2900–2901.
   PubMedGoogle Scholar
• Patino-Navarrete R, Rosinski-Chupin I, Cabanel N, et al. Stepwise evolution and convergent recombination underlie the global dissemination of carbapenemase-producing Escherichia coli. Genome Med. 2020 Jan 20;12(1):10.
   PubMedGoogle Scholar
• Feng Y, Liu L, Lin J, et al. Key evolutionary events in the emergence of a globally disseminated, carbapenem resistant clone in the Escherichia coli ST410 lineage. Commun Biol. 2019;2:322.
   PubMed Web of Science ®Google Scholar
• Pitout JDD, Peirano G, Kock MM, et al. The Global Ascendency of OXA-48-Type Carbapenemases. Clin Microbiol Rev. 2019 Dec 18;33:1.
   Google Scholar
• Denkel LA, Maechler F, Schwab F, et al. Infections caused by extended-spectrum beta-lactamase-producing Enterobacterales after rectal colonization with ESBL-producing Escherichia coli or Klebsiella pneumoniae. Clin Microbiol Infect. 2020 Aug;26(8):1046–1051.
   PubMedGoogle Scholar
• Campos-Madueno EI, Moradi M, Eddoubaji Y, et al. Intestinal colonization with multidrug-resistant Enterobacterales: screening, epidemiology, clinical impact, and strategies to decolonize carriers. Eur J Clin Microbiol Infect Dis. 2023 Mar;42(3):229–254.
   PubMedGoogle Scholar